Twist Bioscience (TWST) P/B ratio

P/B ratio today
7.9×

Twist Bioscience (TWST) trades at 7.9× its book value per share at the end of fiscal 2026. At the end of fiscal 2026 (September 30, 2026) its P/B ratio was 13.6×. That is 282.9% higher than the 3.6× of fiscal 2025. Figures as of 18 Nov 2026, 07:39 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/B ratio today
7.9×
P/B ratio, fiscal 2026
13.6×
Change on fiscal 2025
+282.9%
Highest on record
13.6×fiscal 2026
Lowest on record
1.8×fiscal 2023
Fiscal years on record
72020–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Twist Bioscience P/B ratio, in more detail

Today's figure is 42.0% below the fiscal 2026 year-end.

Across the 7 fiscal year-ends on record (2020–2026), the highest was 13.6× in fiscal 2026 and the lowest 1.8× in fiscal 2023. Today's P/B ratio is higher than at 57% of the 7 fiscal year-ends on record; their median is 5.5×.

History · 7 fiscal years

P/B ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Twist Bioscience P/B ratio, year by year

Twist Bioscience (TWST) P/B ratio by fiscal year
Fiscal yearP/B ratioChangeYear endedShare price at year-endBook value per share
Today7.9×—$112.00—
202613.6× 282.9% up$193.24$14.18
20253.6× 35.8% down$28.14$7.91
20245.5× 200.0% up$45.18$8.15
20231.8× 23.2% down$20.26$10.96
20222.4× 72.9% down$35.24$14.65
20218.9× 0.4% up$106.97$12.04
20208.9×—$75.97$8.58
2019——$23.88—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.

How to read it

It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.

P/B ratio at health care companies of similar size

P/B ratio of Twist Bioscience and comparable companies
CompanyP/B ratio
Praxis Precision Medicines PRAX9.7×
Twist Bioscience TWST8.4×
Protagonist Therapeutics PTGX13.2×
Krystal Biotech KRYS7.3×
10x Genomics TXG9.3×

Today's market value divided by shareholders' equity at the latest fiscal year-end. A company whose statements are in another currency than its shares is left out.

More on TWST

Twist Bioscience, figure by figure

Twist Bioscience (TWST) overview: price, valuation and scorecardAll health care companies by market value

Twist Bioscience P/B ratio: questions and answers

What is Twist Bioscience's P/B ratio?

Twist Bioscience (TWST) trades at 7.9× its book value per share at the end of fiscal 2026. At the end of fiscal 2026 (September 30, 2026) its P/B ratio was 13.6×. That is 282.9% higher than the 3.6× of fiscal 2025.

Is Twist Bioscience's P/B ratio high or low compared with its own history?

Today's P/B ratio is higher than at 57% of the 7 fiscal year-ends on record; their median is 5.5×.

What are the highest and lowest P/B ratio figures on record for Twist Bioscience?

Across the 7 fiscal year-ends on record (2020–2026), the highest was 13.6× in fiscal 2026 and the lowest 1.8× in fiscal 2023.

How is Twist Bioscience's P/B ratio calculated?

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Twist Bioscience (TWST) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/TWST/pb-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.